within Pharmacolibrary.Drugs.ATC.L;

model L01XJ02
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.44,
    Cl             = 5.849999999999999e-05,
    adminDuration  = 600,
    adminMass      = 800 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 9.18,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0003,
    Tlag           = 1800,            
    Vdp             = 3.66,
    k12             = 37.3,
    k21             = 37.3
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01XJ02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Sonidegib is a hedgehog pathway inhibitor used primarily for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) who are not candidates for surgery or radiation therapy. It is an orally bioavailable, small-molecule inhibitor of the Smoothened (SMO) receptor. Sonidegib is approved for use in several countries including the US and EU.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with advanced solid tumors following oral administration. Parameters reflect steady-state kinetics in cancer patients.</p><h4>References</h4><ol><li><p>Goel, V, et al., &amp; Sellami, D (2016). Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors. <i>Cancer chemotherapy and pharmacology</i> 77(4) 745–755. DOI:<a href=\"https://doi.org/10.1007/s00280-016-2982-1\">10.1007/s00280-016-2982-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26898300/\">https://pubmed.ncbi.nlm.nih.gov/26898300</a></p></li><li><p>Pooler, DB, et al., &amp; Lewis, LD (2021). The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours. <i>British journal of clinical pharmacology</i> 87(3) 1291–1302. DOI:<a href=\"https://doi.org/10.1111/bcp.14508\">10.1111/bcp.14508</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32736411/\">https://pubmed.ncbi.nlm.nih.gov/32736411</a></p></li><li><p>Villani, A, et al., &amp; Scalvenzi, M (2021). Expert opinion on sonidegib efficacy, safety and tolerability. <i>Expert opinion on drug safety</i> 20(8) 877–882. DOI:<a href=\"https://doi.org/10.1080/14740338.2021.1921734\">10.1080/14740338.2021.1921734</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33888008/\">https://pubmed.ncbi.nlm.nih.gov/33888008</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01XJ02;
